Gynecologic Oncology Reports最新文献

{"title":"Endometrioid adenocarcinoma of the colon arising from rare malignant transformation of extra-gonadal endometrioma","authors":"Anne Stoklosa ,&nbsp;Youngeun Armbuster ,&nbsp;Lila Marshall ,&nbsp;Jamie L McDowell ,&nbsp;Naixin Zhang ,&nbsp;Ashlee Smith ,&nbsp;Cynthia Angel ,&nbsp;Aaron Varghese ,&nbsp;Wei Huang ,&nbsp;Richard Moore","doi":"10.1016/j.gore.2024.101664","DOIUrl":"10.1016/j.gore.2024.101664","url":null,"abstract":"<div><h3>Background</h3><div>Endometriosis is a common condition with a rare malignant potential. We report a case of a patient with a colon mass who underwent surgery for malignant endometriosis associated cancer.</div><div>Case: A 70-year-old woman with a pelvic mass who was lost to follow-up for 6 years represented with an enlarging pelvic mass involving the sigmoid colon. The patient underwent colonoscopy which revealed atypical endometrial-type glandular proliferation. She then underwent exploratory laparotomy with total abdominal hysterectomy, bilateral salpingo-oophorectomy, rectosigmoid resection, and creation of end colostomy. Final pathology revealed endometrioid adenocarcinoma arising from colon serosal endometriosis. Observation or systemic chemotherapy were considered, and patient opted for observation.</div></div><div><h3>Conclusion</h3><div>We report a case of malignant intestinal endometriosis. There is limited evidence to support a standardized approach to treatment due to the rare nature of this disease; the patient opted for observation. By understanding the presentation, diagnostic workup, and outcomes of each patient with malignant endometriosis, future research can be guided to ultimately improve patient outcomes.</div></div>","PeriodicalId":12873,"journal":{"name":"Gynecologic Oncology Reports","volume":"57 ","pages":"Article 101664"},"PeriodicalIF":1.2,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11750269/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143004349","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Neovaginal squamous cell carcinoma in a transgender woman: Case report, treatment insights, and literature review","authors":"Manengue Arsene ,&nbsp;Nantier Émilie Marie-Christine ,&nbsp;Pelland Marie-Ève ,&nbsp;Beauchemin Marie-Claude ,&nbsp;Bourque Jean-Marc","doi":"10.1016/j.gore.2025.101686","DOIUrl":"10.1016/j.gore.2025.101686","url":null,"abstract":"","PeriodicalId":12873,"journal":{"name":"Gynecologic Oncology Reports","volume":"57 ","pages":"Article 101686"},"PeriodicalIF":1.2,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143127834","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Disparities in the uptake of HPV-related cancer prevention strategies among women by HIV status in Puerto Rico","authors":"Marievelisse Soto-Salgado ,&nbsp;Melisa Ramos-Sepúlveda ,&nbsp;Jeslie M. Ramos-Cartagena ,&nbsp;Maribel Tirado-Gómez ,&nbsp;Humberto M. Guiot ,&nbsp;Cristina Muñoz-Masso ,&nbsp;Lorena González-Sepúlveda ,&nbsp;Ana Patricia Ortiz","doi":"10.1016/j.gore.2025.101687","DOIUrl":"10.1016/j.gore.2025.101687","url":null,"abstract":"<div><h3>Background</h3><div>Women living with HIV (WLWH) are at increased risk of persistent HPV infection and HPV-related cancers than persons without HIV. We aimed to describe the utilization of primary and secondary prevention strategies for HPV-related cancers among women by HIV status in Puerto Rico (PR).</div></div><div><h3>Methods</h3><div>We performed a secondary data analysis of women aged 21+ years (n = 469) evaluated at the Anal Neoplasia Clinic (ANC) of the University of Puerto Rico Comprehensive Cancer Center between 2014 and 2023. The outcomes were history of HPV vaccination, anal Pap screening, and cervical Pap screening in the past 3 years. Descriptive statistics were employed to characterize the study population and comparisons were made by HIV status.</div></div><div><h3>Results</h3><div>Women’s mean age in our study was 50.2 ± 12.1 years; 75.7 % were living with HIV. Among women who were age-eligible for HPV vaccination, 21.7 % reported receiving the HPV vaccine; WLWH were less likely vaccinated than women without HIV (14.7 % vs. 38.7 %, p &lt; 0.01). Prevalence of cervical and anal Pap screening were significantly higher among WLWH (98.6 % and 89.9 %, respectively) than in women without HIV (94.4 % and 47.7 %, respectively). Several risk factors for HPV-related disease were more common among WLWH, such as age at first sexual encounter (≤ 16 years) (54.7 %), more than six lifetime sexual partners (43.1 %), and being a current smoker (23.6 %).</div></div><div><h3>Conclusions</h3><div>Although we observed high uptake of cervical and anal Pap screening in this clinic-based sample, HPV vaccination was deficient. Future studies should involve developing tailored cancer prevention strategies for WLWH to increase HPV vaccination uptake.</div></div>","PeriodicalId":12873,"journal":{"name":"Gynecologic Oncology Reports","volume":"57 ","pages":"Article 101687"},"PeriodicalIF":1.2,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143235114","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Evaluation of reproductive and oncological outcomes after fertility-sparing surgery in cervical cancer patients with tumor > 2 cm","authors":"Kiarash Bahrehmand ,&nbsp;Dóra Vesztergom ,&nbsp;Barna Budai ,&nbsp;Dániel Lengyel ,&nbsp;Edina Lukács ,&nbsp;Zoltán Novák","doi":"10.1016/j.gore.2025.101688","DOIUrl":"10.1016/j.gore.2025.101688","url":null,"abstract":"<div><h3>Background/objectives</h3><div>We aimed to evaluate the reproductive and oncological outcomes of patients who underwent fertility-sparing surgery (FSS) despite being considered suboptimal candidates due to tumor size &gt; 2 cm with or without lymph node metastasis.</div></div><div><h3>Methods</h3><div>Between September 2008 and November 2021, 120 patients with early-stage cervical cancer patients who wished to preserve their fertility, were treated in our center. Out of these, 18 patients were not optimal candidates for FSS according to current guidelines. Despite our proposed radical treatment, these patients insisted on having a fertility-sparing treatment. The primary objective was to evaluate the reproductive outcomes including the method of conception, postoperative pregnancy rate, fertility preservation rate, live birth rate, and preterm delivery rate, while the secondary objective was to evaluate 5-year disease-free survival (DFS) and 5-year overall survival (OS).</div></div><div><h3>Results</h3><div>Out of 18 patients, 5 had lymph node metastasis and 2 of them declined adjuvant chemoradiation. Fertility sparing treatment was successful in 14/18 (77.8 %) patients. Out of the 14, 64.3 % (9/14) tried to conceive, resulting in 2 successful deliveries after in vitro fertilization resulting a live birth rate of 22.2. After a median follow-up of 143.3 months (95 % CI 66–169), the 5-year DFS and OS were 83.3 % (66.1–100) and 93.3 % (80.7–100), respectively.</div></div><div><h3>Conclusions</h3><div>This study highlights the possibility of FSS in patients with suboptimal tumor characteristics for fertility preservation while providing acceptable oncologic outcomes. We found that classical barriers to FSS can be challenged, balancing fertility preservation and oncological outcomes, and argue for personalized approaches to cervical cancer treatment, respecting patient priorities. Further prospective studies are warranted to establish the efficacy and safety of such approaches.</div></div>","PeriodicalId":12873,"journal":{"name":"Gynecologic Oncology Reports","volume":"57 ","pages":"Article 101688"},"PeriodicalIF":1.2,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143235115","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Transforming clinical trial enrollment: Leveraging technology and innovation to reach patients where they are","authors":"Sahana Somasegar,&nbsp;Jamie N. Bakkum-Gamez","doi":"10.1016/j.gore.2025.101691","DOIUrl":"10.1016/j.gore.2025.101691","url":null,"abstract":"","PeriodicalId":12873,"journal":{"name":"Gynecologic Oncology Reports","volume":"57 ","pages":"Article 101691"},"PeriodicalIF":1.2,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143428927","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Challenges and opportunities to address the emerging burden of targeted therapies in ovarian cancer","authors":"Salamatu Abdul-Aziz ,&nbsp;Nawaraj Bhattarai ,&nbsp;Luke Vale ,&nbsp;Gurdeep S Sagoo ,&nbsp;Asima Mukhopadhyay","doi":"10.1016/j.gore.2025.101680","DOIUrl":"10.1016/j.gore.2025.101680","url":null,"abstract":"<div><div>Ovarian cancer (OC) poses a significant socio-economic burden globally with the greatest impact observed in low-and-middle income countries (LMIC). Despite the survival benefit from targeted therapies such as bevacizumab and poly (ADP- ribose) polymerase (PARP) inhibitors, they are associated with high costs to patients and payers which widens the disparities between high and low-income countries. OC treatments may also cause significant morbidity from cytoreductive surgery through to the use of targeted therapies reducing quality of life (QoL). Innovative approaches are necessary to address the increasing burden from the cost and morbidity of OC treatment especially in LMIC. De-escalation of treatment without compromising oncological outcomes could be a strategy to reduce financial cost and morbidity. Moreover, de-escalation techniques integrating the knowledge of pharmacokinetics and pharmacodynamics for dose reduction should be incorporated into clinical trials to identify the minimum effective dose rather than the maximum tolerated with the goal of reducing clinical and financial toxicity. This review summarises the health and economic burden of ovarian cancer with particular reference to LMIC and proposes de-escalation of targeted therapy as a clinical and economic strategy in increasing accessibility and affordability with consideration of patient preferences.</div></div>","PeriodicalId":12873,"journal":{"name":"Gynecologic Oncology Reports","volume":"57 ","pages":"Article 101680"},"PeriodicalIF":1.2,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143180232","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Vulvar keratoacanthoma may be a malignant precursor: A case report and literature review","authors":"Fang Chen ,&nbsp;Yang Wang ,&nbsp;Dina Haishaer ,&nbsp;Feng Bai","doi":"10.1016/j.gore.2024.101674","DOIUrl":"10.1016/j.gore.2024.101674","url":null,"abstract":"<div><h3>Background</h3><div>Keratoacanthoma is a relatively rare skin tumor, with vulvar keratoacanthoma being even more uncommon. Although the majority of keratoacanthomas exhibit a benign course, a subset of cases may show features of malignant potential, such as marginal invasion and recurrence.</div></div><div><h3>Case</h3><div>An 82-year-old female presented with a rapidly growing exophytic lesion on the left vulva, measuring 1.5 cm in diameter, accompanied by pruritus. The lesion had been present for two months. The patient underwent vulvar mass excision, and postoperative pathology revealed squamous cell hyperplasia with glassy cytoplasm and no significant cellular atypia. The surgical margins were clear. Three years later, the tumor recurred with disordered growth.</div></div><div><h3>Conclusion</h3><div>In terms of histological and clinical presentation, keratoacanthoma may overlap with classical well-differentiated squamous cell carcinoma. In rare cases, certain atypical keratoacanthomas may exhibit intravascular and perineural invasion, along with lymph node metastasis. By sharing our treatment experience of a patient with recurrent vulvar keratoacanthoma following surgery, we aim to provide a cautionary perspective for the clinical management of such cases.</div></div>","PeriodicalId":12873,"journal":{"name":"Gynecologic Oncology Reports","volume":"57 ","pages":"Article 101674"},"PeriodicalIF":1.2,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11753976/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143028649","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Molecular characterization of ovarian mesonephric-like adenocarcinoma: Insights from single-cell RNA sequencing and mitochondrial metabolism","authors":"Gwan Hee Han ,&nbsp;Ye-Ah Kim ,&nbsp;Hyunjin Park ,&nbsp;Hee Yun ,&nbsp;Jae-Hoon Kim ,&nbsp;Man S. Kim ,&nbsp;Hanbyoul Cho","doi":"10.1016/j.gore.2024.101670","DOIUrl":"10.1016/j.gore.2024.101670","url":null,"abstract":"<div><h3>Objectives</h3><div>Ovarian mesonephric-like adenocarcinoma (MLA) is a rare malignancy with limited understanding of its molecular features and therapeutic vulnerabilities. Although similar to uterine MLA, its unique characteristics remain undefined. This study aimed to characterize ovarian MLA using single-cell RNA sequencing (scRNA-seq) and compare it with high-grade serous ovarian cancer (HGSOC).</div></div><div><h3>Methods</h3><div>We analyzed the cellular and molecular heterogeneity of an ovarian MLA sample using scRNA-seq. Differential gene expression and pathway analyses were performed to identify unique molecular signatures and therapeutic targets. HGSOC scRNA-seq datasets were used for comparative analysis.</div></div><div><h3>Results</h3><div>Ovarian MLA demonstrated reduced heterogeneity, with a predominance of epithelial cells compared to HGSOC. Transcriptomic profiling revealed an upregulation of mitochondrial metabolism and lipid biosynthesis genes, indicating a metabolic shift toward oxidative phosphorylation. Gene enrichment and protein–protein interaction analyses identified distinct pathways, including mitochondrial biogenesis and dynamics, suggesting mitochondrial reprogramming.</div></div><div><h3>Conclusions</h3><div>This study provides the first scRNA-seq-based molecular characterization of ovarian MLA, differentiating it from HGSOC. Findings suggest potential therapeutic avenues, with a proposed combination therapy targeting MAP kinase and PI3K/AKT/mTOR pathways. Validation in larger cohorts is necessary for clinical application.</div></div>","PeriodicalId":12873,"journal":{"name":"Gynecologic Oncology Reports","volume":"57 ","pages":"Article 101670"},"PeriodicalIF":1.2,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11782955/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143079455","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Adenoid basal cell carcinoma: An underrecognized cervical malignancy","authors":"Arielle Katcher ,&nbsp;Juliana Schilsky ,&nbsp;Alisha Daroch ,&nbsp;Tahyna Hernandez ,&nbsp;Andrew Menzin ,&nbsp;Lisa Dos Santos ,&nbsp;Jill Whyte ,&nbsp;Marina Frimer","doi":"10.1016/j.gore.2024.101667","DOIUrl":"10.1016/j.gore.2024.101667","url":null,"abstract":"<div><h3>Introduction</h3><div>Adenoid basal cell carcinoma is a rare cervical malignancy which is indolent in nature but resembles more commonly occurring aggressive malignancies.</div></div><div><h3>Cases</h3><div>Here we describe three cases of cervical adenoid basal cell carcinoma. All patients had a history of cervical dysplasia with high-risk HPV. The first and second patient were treated with hysterectomy, and the third patient opted for surveillance after cold knife conization. All patients have no evidence of disease to date.</div></div><div><h3>Conclusion</h3><div>Cervical adenoid basal cell carcinoma is a rare malignancy that requires careful diagnostic attention due to its histologic similarities to more aggressive malignancies and the risk of misclassification. Advances in diagnostic criteria including immunohistochemistry (IHC) classification are key to distinguishing this unique pathological entity. Definitive treatment depends on accurate diagnosis. Optimal treatment involves surgical management with hysterectomy and lymph node assessment. Excisional biopsy with thorough pathologic evaluation for invasive carcinoma can be considered in patients who desire future fertility.</div></div>","PeriodicalId":12873,"journal":{"name":"Gynecologic Oncology Reports","volume":"57 ","pages":"Article 101667"},"PeriodicalIF":1.2,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11732580/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142983231","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Ocular surface disease related to tisotumab vedotin-tftv","authors":"Daniella Lent-Schochet ,&nbsp;Shachar Tauber ,&nbsp;Zachary Seagrave ,&nbsp;Grace L. Paley ,&nbsp;Asim V. Farooq","doi":"10.1016/j.gore.2025.101676","DOIUrl":"10.1016/j.gore.2025.101676","url":null,"abstract":"<div><h3>Introduction</h3><div>To report a series of patients who developed ocular surface disease related to tisotumab vedotin-tftv (TV), an antibody-drug conjugate (ADC) approved for the treatment of recurrent or metastatic cervical cancer.</div></div><div><h3>Methods</h3><div>This was a multicenter retrospective chart review study of patients who developed ocular surface disease related to TV between April 1st, 2022 to August 31st, 2023.</div></div><div><h3>Results</h3><div>Five patients were identified who developed ocular surface disease while on TV. All patients received a standard ocular adverse event prophylaxis regimen with each infusion per the product label, including a cool ocular compress, topical vasoconstrictor, topical steroid, and artificial tears. All five patients developed conjunctival subepithelial fibrosis. Two patients developed bilateral pseudomembranous conjunctivitis, one of whom subsequently developed conjunctival scarring. Two patients developed a bilateral culture positive conjunctivitis, which responded to topical antibiotics. One patient developed bilateral infectious keratitis and was treated with partial thickness corneal transplantation of both eyes.</div></div><div><h3>Conclusion</h3><div>TV can be associated with ocular surface disease, including conjunctival scarring and infectious keratitis. Some cases may require surgical intervention. Oncologists and ophthalmologists should be aware of the possibility of these ocular complications, especially as more ADCs are approved. Further studies are required to determine toxicity mechanisms as well as optimal prophylaxis and management strategies.</div></div>","PeriodicalId":12873,"journal":{"name":"Gynecologic Oncology Reports","volume":"57 ","pages":"Article 101676"},"PeriodicalIF":1.2,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11773263/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143058872","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}